Podrobno

Economic burden of heart failure in Europe : a systematic review of costs and cost-effectiveness
ID Darbà, Josep (Avtor), ID Ascanio, Meritxell (Avtor), ID Charman, Sarah Jane (Avtor), ID Bosnić, Zoran (Avtor), ID Vračar, Petar (Avtor)

.pdfPDF - Predstavitvena datoteka, prenos (874,42 KB)
MD5: EC62302498FCEA8F1CF3D6435AB06D21
URLURL - Izvorni URL, za dostop obiščite https://onlinelibrary.wiley.com/doi/10.1002/ehf2.70017 Povezava se odpre v novem oknu

Izvleček
Heart failure (HF) affects over 64 million individuals worldwide and is a major cause of hospitalization and mortality, particularly among older adults. In Europe, HF imposes a significant and growing economic burden. This systematic review aimed to evaluate the economic impact of HF diagnosis, treatment and management across European healthcare systems. A systematic literature search was conducted using PubMed, Cochrane Library and Econlit databases including the terms ‘heart failure’ AND ‘costs’ OR ‘cost of illness’ OR ‘cost analysis’ OR ‘economic burden’ OR ‘cost effectiveness’ OR ‘primary care’ OR ‘secondary care’. Studies published between January 2000 and January 2024 were included. A total of 49 studies were included: 17 on resource use, 11 on costs, 15 on resource use and costs, 1 on costs and cost-effectiveness, and 5 on resource use, costs and cost-effectiveness. Hospitalizations and medication use were the most frequently reported resource parameters. Annual HF-related costs varied widely across countries, ranging from €613 to €22,647 per patient. Hospitalizations represented the primary cost driver, accounting for 15% to 92% of total HF costs. Cost-reduction strategies included multidisciplinary care, telemonitoring and pharmacologic interventions. Several disease management programmes reduced hospital admissions and emergency visits. Cost-effectiveness analyses supported the use of certain HF therapies, with incremental cost-effectiveness ratios ranging from €1490 to €9406 per QALY gained. F imposes a substantial economic burden in Europe, largely driven by hospitalizations. Cost-effective interventions such as remote monitoring and integrated care programmes can reduce this burden. Broader adoption of these strategies may improve outcomes and optimize resource allocation across healthcare systems.

Jezik:Angleški jezik
Ključne besede:heart failure, healthcare costs, cost effectiveness, economic burden
Vrsta gradiva:Članek v reviji
Tipologija:1.02 - Pregledni znanstveni članek
Organizacija:FRI - Fakulteta za računalništvo in informatiko
Status publikacije:Objavljeno
Različica publikacije:Objavljena publikacija
Leto izida:2025
Št. strani:14 str.
Številčenje:Vol. , no.
PID:20.500.12556/RUL-176658 Povezava se odpre v novem oknu
UDK:616.12-008.46:614.2:33
ISSN pri članku:2055-5822
DOI:10.1002/ehf2.70017 Povezava se odpre v novem oknu
COBISS.SI-ID:259113731 Povezava se odpre v novem oknu
Datum objave v RUL:08.12.2025
Število ogledov:70
Število prenosov:17
Metapodatki:XML DC-XML DC-RDF
:
Kopiraj citat
Objavi na:Bookmark and Share

Gradivo je del revije

Naslov:ESC heart failure
Založnik:J. Wiley & Sons
ISSN:2055-5822
COBISS.SI-ID:523661593 Povezava se odpre v novem oknu

Licence

Licenca:CC BY 4.0, Creative Commons Priznanje avtorstva 4.0 Mednarodna
Povezava:http://creativecommons.org/licenses/by/4.0/deed.sl
Opis:To je standardna licenca Creative Commons, ki daje uporabnikom največ možnosti za nadaljnjo uporabo dela, pri čemer morajo navesti avtorja.

Sekundarni jezik

Jezik:Slovenski jezik
Ključne besede:srčna odpoved, stroški zdravljenja, cenovna učinkovitost, finančno breme

Projekti

Financer:EC - European Commission
Številka projekta:101080905
Naslov:Artificial intelligence-based decision support system for risk stratification and early detection of heart failure in primary and secondary care
Akronim:STRATIFYHF

Financer:UKRI - UK Research and Innovation
Številka projekta:10073472
Naslov:STRATIFYHF: Artificial intelligence-based decision support system for risk stratification and early detection of heart failure in primary and secondary care

Financer:Drugi - Drug financer ali več financerjev
Program financ.:Swiss State Secretariat for Education, Research and Innovation
Številka projekta:/
Naslov:/

Financer:Drugi - Drug financer ali več financerjev
Program financ.:National Institute for Health Research, Biomedical Research Centre
Številka projekta:NIHR BRC
Naslov:National Institute for Health Research, Biomedical Research Centre
Akronim:NIHR BRC

Podobna dela

Podobna dela v RUL:
Podobna dela v drugih slovenskih zbirkah:

Nazaj